Filed by Elscint Ltd. Pursuant to Rule 425
                                      Under the Securities Act of 1933
                                      And deemed filed pursuant to Rule 14a-12
                                      Under the Securities Exchange Act of 1934
                                      Subject Company: Elscint Ltd.
                                      Commission File No.: 001-08781

               ELSCINT LIMITED ANNOUNCES CLOSING OF THE MERGER BY
            WAY OF EXCHANGE OF SHARES WITH ELBIT MEDICAL IMAGING LTD.

      Tel Aviv, Israel - November 23, 2005 - Elscint Limited (NYSE: ELT)
("Elscint") announced today the closing of the merger by way of an exchange of
shares between Elscint and Elbit Medical Imaging Ltd. ("EMI"), the indirect
controlling shareholder of Elscint.

      As of the date hereof, Elscint ordinary shares have ceased to trade on the
New York Stock Exchange and Elscint became a wholly-owned subsidiary of EMI.

The Chairman of Elscint's Board of Directors, Abraham (Rami) Goren, commented:
"We are happy to complete this merger. We believe that the combined company will
benefit from greater resources and opportunities as a result of the merger".

About Elscint Limited

Elscint Limited is engaged in two principal businesses: Hotel development and
leisure, and investments in bio-technology companies. Elscint has interests in
hotels in Western Europe, in hotel development projects, principally in Western
and Central Europe, and in the commercial and entertainment center at the Marina
in Herzlia, Israel. In the bio-technology field, Elscint invests in high
potential start-up companies, and provides business guidance and professional
advice to such companies for the development of business plans, research and
development and marketing programs. More information regarding the Company is
available at: http://www.elscint.net

This release contains certain forward-looking statements, which involve known
and unknown risks, uncertainties or other factors not under the Company's
control. The Company does not undertake to update the information set forth in
this release.

For Further Information:

Company Contact                          Investor Contact

Abraham (Rami) Goren                     Kathy Price
Elscint, Ltd.                            The Global Consulting Group
+972-3-608-6020                          +1-646-284-9430
argoren@elscint.net                      kprice@hfgcg.com
- -------------------                      ----------------